Last reviewed · How we verify
Acnatac® Gel left face
Acnatac® Gel combines clindamycin (an antibiotic) and benzoyl peroxide (an antimicrobial oxidizing agent) to reduce acne-causing bacteria and inflammation on the skin.
Acnatac® Gel combines clindamycin (an antibiotic) and benzoyl peroxide (an antimicrobial oxidizing agent) to reduce acne-causing bacteria and inflammation on the skin. Used for Acne vulgaris.
At a glance
| Generic name | Acnatac® Gel left face |
|---|---|
| Also known as | Clindamycin 1%, Tretinoin 0,025% |
| Sponsor | GWT-TUD GmbH |
| Drug class | Topical antibiotic combination |
| Target | Bacterial ribosome (clindamycin); oxidative stress induction (benzoyl peroxide) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Clindamycin inhibits bacterial protein synthesis, reducing Propionibacterium acnes colonization, while benzoyl peroxide generates reactive oxygen species that kill bacteria and help prevent antibiotic resistance. Together, they address both the bacterial and inflammatory components of acne vulgaris.
Approved indications
- Acne vulgaris
Common side effects
- Skin irritation
- Erythema
- Dryness
- Peeling
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Acnatac® Gel left face CI brief — competitive landscape report
- Acnatac® Gel left face updates RSS · CI watch RSS
- GWT-TUD GmbH portfolio CI